Kiri Granger
Co-Founder & Chief Scientific Officer Monument Therapeutics
With 10 years of industry experience, Kiri is a highly regarded expert in the CNS field, particularly in schizophrenia. During her role as Director of Neuroscience at Cambridge Cognition, she was lead scientist on over 100 clinical trial programs and gained recognition for her innovative strategies that successfully demonstrated the efficacy of compounds following negative trial results.
During her PhD at the University of Nottingham, Kiri developed the biomarker that is now integral to Monument’s schizophrenia program, helping to establish the company’s precision medicine approach. She is an inventor on multiple patents and serves as Assistant Professor in the Department of Psychology at the University of Nottingham, reflecting her commitment to advancing research in neuroscience.
Seminars
- How to define the unmet need for biomarkers in neurological diseases so that patient eligibility for novel therapies is better established and trial recruitment becomes more efficient?
- How to leverage diagnostic platforms such as mass spectrometry or high-sensitivity immunoassays so that biomarker measurements become more standardised and comparable across trials, enabling broader clinical adoption?
- What is the regulatory pathway in Europe for neurological biomarkers compared with oncology?
